Skip to main content

Rilonacept Side Effects

Medically reviewed by Last updated on May 18, 2023.

Applies to rilonacept: subcutaneous powder for solution.

Serious side effects of Rilonacept

Along with its needed effects, rilonacept may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking rilonacept:

More common

Less common

Incidence not known

Other side effects of Rilonacept

Some side effects of rilonacept may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to rilonacept: subcutaneous powder for injection.


Very common (10% or more): Injection site reactions (e.g., erythema, swelling, pruritus, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles, warmth, hemorrhage) (48%)[Ref]

In patients with Cryopyrin-Associated Periodic Syndromes (CAPS), the most common and consistently reported adverse event associated with rilonacept was injection-site reaction (ISR). The ISRs included erythema, swelling, pruritus, mass, bruising, inflammation, pain, edema, dermatitis, discomfort, urticaria, vesicles, warmth, and hemorrhage. Most injection-site reactions lasted for one to two days. No ISRs were assessed as severe, and no patient discontinued study participation due to an ISR.[Ref]


Very common (10% or more): Infection (34%)[Ref]

One subject receiving rilonacept for an unapproved indication developed an infection in his olecranon bursa with Mycobacterium intracellulare. The patient was on chronic glucocorticoid treatment. The infection occurred after an intraarticular glucocorticoid injection into the bursa with subsequent local exposure to a suspected source of mycobacteria. The patient recovered after the administration of the appropriate antimicrobial therapy.

A patient treated for another unapproved indication developed bronchitis/sinusitis, which resulted in hospitalization.

One patient died in an open-label study of CAPS from Streptococcus pneumoniae meningitis.[Ref]


Very common (10% or more): Upper respiratory tract infection (26%)

Common (1% to 10%): Sinusitis, cough[Ref]

Nervous system

Common (1% to 10%): Hypoesthesia[Ref]


Common (1% to 10%): Nausea, diarrhea, stomach disorder[Ref]


Frequency not reported: Neutropenia[Ref]

The patient did not experience any infection associated with the neutropenia.

Physicians should monitor the lipid profiles of their patients (for example after 2 to 3 months) and consider lipid-lowering therapies as needed based upon cardiovascular risk factors and current guidelines.[Ref]


Common (1% to 10%): Urinary tract infection[Ref]


Rare (less than 0.1%): Hypersensitivity[Ref]


Frequency not reported: Increased mean total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides (in patients with CAPS)[Ref]


The most commonly reported adverse reaction is injection-site reaction (ISR). The next most commonly reported adverse reaction is upper respiratory infection.[Ref]


1. (2008) "Product Information. Arcalyst (rilonacept)." Regeneron Pharmaceuticals Inc

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.